Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs | GenomeWeb

Originally published May 4.

Following the merger of two behemoths of the pharmacy-benefits management industry, Medco's leadership role in conducting clinical utility research for genomically guided personalized medicine will likely be scaled back to align with Express Script's more conservative view of the market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.